Harmony Biosciences Holdings (HRMY) Receivables (2019 - 2026)
Harmony Biosciences Holdings (HRMY) posted Receivables of $108.2 million for Q1 2026, up 11.81% sequentially from $96.8 million in Q4 2025, and up 2.13% YoY from $106.0 million in Q1 2025.
Harmony Biosciences Holdings (HRMY) Receivables (2019 - 2026) Analysis & Trends
Harmony Biosciences Holdings has reported Receivables for 8 years, with the latest figure at $108.2 million in Q1 2026.
- Quarterly Receivables rose 2.13% year-over-year to $108.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $108.2 million (up 2.13% YoY) and the FY2025 annual result came in at $96.8 million, up 16.56% from the prior year.
- Receivables improved to $108.2 million in Q1 2026 per HRMY's latest filing, from $96.8 million in the prior quarter.
- Over five years, Receivables peaked at $108.2 million in Q1 2026 and troughed at $38.1 million in Q1 2022.
- A 5-year average of $75.7 million and a median of $79.7 million in 2024 frame the typical range for Receivables.
- The sharpest annual moves came in 2022 and 2026: Receivables jumped 65.83% in 2022, then rose 2.13% in 2026.
- Over 5 years, Receivables stood at $54.7 million in 2022, then surged by 35.44% to $74.1 million in 2023, then gained by 11.99% to $83.0 million in 2024, then climbed by 16.56% to $96.8 million in 2025, then climbed by 11.81% to $108.2 million in 2026.
- According to Business Quant data, Receivables over the past three periods registered $108.2 million, $96.8 million, and $100.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Harmony Biosciences Holdings | 2.22 Bn | 1.41 Bn | 198.08 Mn | 111.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 111.00 Mn |
| Mar 31, 2026 | 108.22 Mn |
| Dec 31, 2025 | 96.79 Mn |
| Sep 30, 2025 | 100.65 Mn |
| Jun 30, 2025 | 92.98 Mn |
| Mar 31, 2025 | 105.97 Mn |
| Dec 31, 2024 | 83.03 Mn |
| Sep 30, 2024 | 81.50 Mn |
| Jun 30, 2024 | 83.16 Mn |
| Mar 31, 2024 | 79.72 Mn |
| Dec 31, 2023 | 74.14 Mn |
| Sep 30, 2023 | 67.26 Mn |
| Jun 30, 2023 | 63.81 Mn |
| Mar 31, 2023 | 52.58 Mn |
| Dec 31, 2022 | 54.74 Mn |
| Sep 30, 2022 | 55.07 Mn |
| Jun 30, 2022 | 49.82 Mn |
| Mar 31, 2022 | 38.13 Mn |
| Dec 31, 2021 | 34.84 Mn |
| Sep 30, 2021 | 33.21 Mn |